Stocks to End the Opioid Epidemic (NASDAQ: ECOR) (NASDAQ: PCRX) (OTC: ENDV) (NASDAQ: NVCR)

Stocks to End the Opioid Epidemic (NASDAQ: ECOR) (NASDAQ: PCRX) (OTC: ENDV) (NASDAQ: NVCR)

Oct 14, 2020 (OTC PR WIRE via COMTEX) —

Opioid drugs have done more damage over the last few years than Covid-19. But now, because of the pandemic, the opioid crisis has significantly worsened, with experts looking for an increase in negative results, including overdoses and deaths from overdoses due to many feeling locked down, laid off, and flooded with uncertainty. So far, according to research from the AAMC, experts see signs of relapses, rising overdoses, and other worries.

That shift takes root from an already crisis-level state of affairs. According to data from the National Institutes of Health (NIH), in 2018 over 128 people died each day from opioid-related drug overdose.

Most of this has its roots in chronic pain. Over 100 million Americans suffer from some form of chronic pain. Globally, and experts believe the chronic pain market is an opportunity expected to grow to $69 – $105 billion over coming years. But current solutions to this epidemic are woefully inadequate.

The key is to provide new solutions for related health conditions that don’t amount to a recruiting operation for the next crop of addicts on the rails toward potential life crisis or overdose. There must be a better way.

Here, we present some of the stocks seeing significant current or coming growth based on their non-opioid solutions, including: electroCore Inc. (NASDAQ: ECOR), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Endonovo Therapeutics Inc. (OTC: ENDV), and Novocure Ltd. (NASDAQ: NVCR).

electroCore Inc. (NASDAQ: ECOR) trumpets itself as a commercial stage medical device company that engages in the development and commercialization of a range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies.

The company is developing gammaCore, a prescription-only nVNS therapy for the acute

Read More Here...

Bookmark the permalink.

Comments are closed.